Research programme: soluble CD83 - Argos Therapeutics/Beckman Coulter

Drug Profile

Research programme: soluble CD83 - Argos Therapeutics/Beckman Coulter

Alternative Names: AGS-010; sCD83

Latest Information Update: 30 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beckman Coulter
  • Developer Argos Therapeutics Inc
  • Class CD antigens; Immunoglobulins; Membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Transplant rejection

Highest Development Phases

  • Preclinical Autoimmune disorders; Transplant rejection

Most Recent Events

  • 15 Aug 2013 Preclinical trials in Transplant rejection in USA (Ophthalmic)
  • 15 Aug 2013 Pharmacodynamics data from preclinical trials in Transplant rejection released by Argos Therapeutics
  • 06 May 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top